Single Ventricle Heart Disease Clinical Trial
Official title:
Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL-2)
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
This study is a 26 week, prospective, multicenter, randomized, double-blinded, placebo-controlled safety and efficacy study of udenafil vs. placebo in adolescent subjects who have had the Fontan procedure. The primary efficacy endpoint will be change from baseline at 26 weeks in peak minute oxygen consumption (VO2 mL/kg/min) as measured by maximal cardiopulmonary exercise test (CPET) reading laboratory who will be blinded to treatment allocation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05199857 -
WE BEAT - HEART Club Fontan Wellness Project: A Virtual Resilience Promotion and Frailty Prevention Program
|
N/A | |
| Completed |
NCT03687008 -
Cognitive Intervention to Improve Working Memory
|
N/A | |
| Completed |
NCT02741115 -
Fontan Udenafil Exercise Longitudinal Assessment Trial
|
Phase 3 | |
| Active, not recruiting |
NCT03430583 -
Evaluation of Fontan-Associated Liver Disease
|